W Advisors, LLC Bristol Myers Squibb CO Transaction History

W Advisors, LLC

$152 Million
Q2 2024

A detailed history of W Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, W Advisors, LLC holds 19,986 shares of BMY stock, worth $1.06 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares

19,986

Previous 19,810 0.89%

Holding current value

$1.06 Million

Previous $1.07 Million 22.72%

% of portfolio

0.55%

Previous 0.74%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$40.25 - $52.99 $7,084 - $9,326	176 Added 0.89%	19,986 $830,000
Q1 2024 Apr 25, 2024	BUY	$47.98 - $54.4 $3,502 - $3,971	73 Added 0.37%	19,810 $1.07 Million
Q4 2023 Feb 06, 2024	BUY	$48.48 - $57.85 $6,835 - $8,156	141 Added 0.72%	19,737 $1.01 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $124,868 - $139,622	-2,157 Reduced 9.92%	19,596 $1.14 Million
Q2 2023 Aug 03, 2023	BUY	$63.71 - $70.74 $8,791 - $9,762	138 Added 0.64%	21,753 $1.39 Million
Q1 2023 Aug 07, 2023	SELL	$65.71 - $74.53 $6,768 - $7,676	-103 Reduced 0.47%	21,650 $1.5 Million
Q4 2022 Feb 06, 2023	SELL	$68.48 - $81.09 $167,228 - $198,021	-2,442 Reduced 10.15%	21,615 $1.55 Million
Q3 2022 Oct 24, 2022	SELL	$0.13 - $76.84 $27 - $16,366	-213 Reduced 0.88%	24,057 $1.71 Million
Q2 2022 Aug 26, 2022	BUY	$72.62 - $79.98 $10,021 - $11,037	138 Added 0.57%	24,270 $1.87 Million
Q1 2022 Aug 26, 2022	BUY	$61.48 - $73.72 $63,693 - $76,373	1,036 Added 4.49%	24,132 $1.76 Million
Q4 2021 Aug 15, 2022	BUY	$53.63 - $62.52 $1.24 Million - $1.44 Million	23,096 New	23,096 $1.44 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of W Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on W Advisors, LLC with notifications on news.

Account